Hashimoto N, Kobayashi M, Tsuji T
First Department of Internal Medicine, Okayama University Medical School, Japan.
Acta Med Okayama. 1988 Feb;42(1):1-6. doi: 10.18926/AMO/31039.
The activity of serum type IV collagen-degrading enzyme was measured in 18 patients with hepatocellular carcinoma (HCC). The enzyme activity was significantly higher, in HCC patients with a tumor thrombus in the portal vein than in healthy controls, liver cirrhosis patients and HCC patients without a tumor thrombus. Moreover, the activity in HCC patients with lung metastasis tended to be higher than that in HCC patients without lung metastasis. The activity of serum type IV collagen-degrading enzyme did not correlate with tumor size, serum alpha-fetoprotein level, or macroscopic classification of tumor growth. These results suggest that the activity of serum type IV collagen-degrading enzyme represents the metastatic potential or the ongoing metastatic activity of HCC. The enzyme is a useful serum marker of metastasis from HCC.
对18例肝细胞癌（HCC）患者测定了血清IV型胶原降解酶的活性。门静脉有癌栓的HCC患者的酶活性显著高于健康对照者、肝硬化患者以及无癌栓的HCC患者。此外，有肺转移的HCC患者的酶活性往往高于无肺转移的HCC患者。血清IV型胶原降解酶的活性与肿瘤大小、血清甲胎蛋白水平或肿瘤生长的大体分类无关。这些结果表明，血清IV型胶原降解酶的活性代表了HCC的转移潜能或正在进行的转移活性。该酶是HCC转移的一种有用的血清标志物。
